OKG Capital
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
OXcan
9 Jan 2025
OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection
OXcan develops blood-based liquid biopsy tests using proteomics and AI to detect lung cancer at earlier stages, enabling minimally invasive screening designed to improve outcomes and reduce pressure on healthcare systems.
52North
6 Dec 2024
Oncology medical tech startup 52North secures £5m with landmark UK-US hospital VC deal
52North builds medical devices and digital tools that support cancer patients outside hospital, focusing on early detection and monitoring of treatment-related complications to improve urgent oncology care pathways.
More venture news
- 21 Jul 2026
HumanoidHumanoid unlocks £114m Series A led by Prime Movers Lab to deploy humanoid robots across industrial manufacturing and logistics
Series AIndustrial - 22 Jul 2026
ArrakisArrakis raises a £22m Series A led by Blossom Capital to install AI agents into industrial companies' mission-critical operations
Series AIndustrial - 13 Jul 2026
ReformedReformed closes £17m Series A from IRIS Ventures for its functional coffee and matcha subscriptions
Series AConsumer
